Related references
Note: Only part of the references are listed.Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel
Viktor Soukup et al.
EUROPEAN UROLOGY FOCUS (2020)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer
Alexander C. Dowell et al.
PLOS ONE (2017)
Future directions in bladder cancer immunotherapy: towards adaptive immunity
Sean G. Smith et al.
IMMUNOTHERAPY (2016)
Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations
Wassim Kassouf et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2016)
Simultaneous multi-analyte urinary protein assay for bladder cancer detection
Charles J. Rosser et al.
BMC BIOTECHNOLOGY (2014)
Myths and Mysteries Surrounding Bacillus Calmette-Guerin Therapy for Bladder Cancer
Ashish M. Kamat et al.
EUROPEAN UROLOGY (2014)
CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging
S. Parviainen et al.
GENE THERAPY (2014)
Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal
Peter Valent et al.
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2012)
Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer
Claire Biot et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy
Bas W. G. van Rhijn et al.
EUROPEAN UROLOGY (2009)
Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin:: Multivariate analysis of data from four randomized CUETO trials
Jesus Fernandez-Gomez et al.
EUROPEAN UROLOGY (2008)
The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy
FN Joudi et al.
JOURNAL OF UROLOGY (2006)
Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study
DL Lamm et al.
JOURNAL OF UROLOGY (2000)
Share Paper
